Research & Literature

Endocrine tumours: familial nonmedullary thyroid carcinoma is a more aggressive disease: a systematic review and meta-analysis.

Wang X, Cheng W, Li J, et al.

European journal of endocrinology 2015; (172(6)):R253-62 doi:10.1530/EJE-14-0960.

SERIAL NECK ULTRASOUND IS MORE LIKELY TO IDENTIFY FALSE-POSITIVE ABNORMALITIES THAN CLINICALLY SIGNIFICANT DISEASE IN LOW-RISK PAPILLARY THYROID CANCER PATIENTS.

Yang SP, Bach AM, Tuttle RM, Fish SA

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2015; (21(12)):1372-9 doi:10.4158/EP15851.OR.

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Haugen BR, Alexander EK, Bible KC, et al.

Thyroid : official journal of the American Thyroid Association 2016; (26(1)):1-133 doi:10.1089/thy.2015.0020.

Cribiform variant of papillary thyroid cancer and familial adenomatous polyposis.

Perea Del Pozo E, Ramirez Plaza C, Padillo Ruiz J, Martos Martínez JM

International journal of surgery case reports 2015; (16()):192-4.

Targeted DNA Sequencing Detects Mutations Related to Susceptibility among Familial Non-medullary Thyroid Cancer.

Yu Y, Dong L, Li D, et al.

Scientific reports 2015; (5()):16129 doi:10.1038/srep16129.

HABP2 G534E Variant in Papillary Thyroid Carcinoma.

Tomsic J, Fultz R, Liyanarachchi S, et al.

PloS one 2016; (11(1)):e0146315 doi:10.1371/journal.pone.0146315.

Family Screening in Familial Papillary Carcinoma: The Early Detection of Thyroid Disease.

Ríos A, Rodríguez JM, Navas D, et al.

Annals of surgical oncology 2016; (23(8)):2564-70 doi:10.1245/s10434-016-5149-8.

HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer.

Weeks AL, Wilson SG, Ward L, et al.

BMC medical genetics 2016; (17(1)):60 doi:10.1186/s12881-016-0323-1.

The impact of family history on non-medullary thyroid cancer.

Nixon IJ, Suárez C, Simo R, et al.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2016; (42(10)):1455-63.

Clinical significance of prophylactic central compartment neck dissection in the treatment of clinically node-negative papillary thyroid cancer patients.

Gambardella C, Tartaglia E, Nunziata A, et al.

World journal of surgical oncology 2016; (14(1)):247 doi:10.1186/s12957-016-1003-5.

Familial non-medullary thyroid cancer: unraveling the genetic maze.

Peiling Yang S, Ngeow J

Endocrine-related cancer 2016; (23(12)):R577-R595 doi:10.1530/ERC-16-0067.

Genotype Analyses in the Japanese and Belarusian Populations Reveal Independent Effects of rs965513 and rs1867277 but Do Not Support the Role of FOXE1 Polyalanine Tract Length in Conferring Risk for Papillary Thyroid Carcinoma.

Nikitski AV, Rogounovitch TI, Bychkov A, et al.

Thyroid : official journal of the American Thyroid Association 2017; (27(2)):224-235 doi:10.1089/thy.2015.0541.

Quantification of Thyroid Cancer and Multinodular Goiter Risk in the DICER1 Syndrome: A Family-Based Cohort Study.

Khan NE, Bauer AJ, Schultz KAP, et al.

The Journal of clinical endocrinology and metabolism 2017; (102(5)):1614-1622 doi:10.1210/jc.2016-2954.

[A Familial Non Medullary Thyroid Carcinoma (FNMTC) : a clinical and genetic update].

Valdes-Socin H, Palmeira L, Burlacu MC, et al.

Revue medicale de Liege 2016; (71(12)):557-561.

Surgical management of papillary thyroid carcinoma: an overview.

Miccoli P, Bakkar S

Updates in surgery 2017; (69(2)):145-150 doi:10.1007/s13304-017-0449-5.

PTEN, DICER1, FH, and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood.

Schultz KAP, Rednam SP, Kamihara J, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2017; (23(12)):e76-e82 doi:10.1158/1078-0432.CCR-17-0629.

Results of Screening in Familial Non-Medullary Thyroid Cancer.

Klubo-Gwiezdzinska J, Yang L, Merkel R, et al.

Thyroid : official journal of the American Thyroid Association 2017; (27(8)):1017-1024 doi:10.1089/thy.2016.0668.

Genome-wide association and expression quantitative trait loci studies identify multiple susceptibility loci for thyroid cancer.

Son HY, Hwangbo Y, Yoo SK, et al.

Nature communications 2017; (8()):15966 doi:10.1038/ncomms15966.

Familial Nonmedullary Thyroid Carcinoma: A Retrospective Analysis of 117 Families.

Zhang YB, Wang XX, Zhang XW, et al.

Chinese medical journal 2018; (131(4)):395-401 doi:10.4103/0366-6999.225054.

Prophylactic Central Compartment Neck Dissection in Papillary Thyroid Cancer and Effect on Locoregional Recurrence.

Hughes DT, Rosen JE, Evans DB, et al.

Annals of surgical oncology 2018; (25(9)):2526-2534 doi:10.1245/s10434-018-6528-0.

Clinical implications of anti-thyroglobulin antibody measurement before surgery in thyroid cancer.

Jo K, Lim DJ

The Korean journal of internal medicine 2018; (33(6)):1050-1057 doi:10.3904/kjim.2018.289.

An update on familial nonmedullary thyroid cancer.

Ammar SA, Alobuia WM, Kebebew E

Endocrine 2020; (68(3)):502-507 doi:10.1007/s12020-020-02250-3.

[Hereditary predispositions to follicular thyroid tumors].

Decaussin-Petrucci M

Annales de pathologie 2020; (40(2)):142-147 doi:10.1016/j.annpat.2020.02.011.

BROX haploinsufficiency in familial nonmedullary thyroid cancer.

Pasquali D, Torella A, Accardo G, et al.

Journal of endocrinological investigation 2021; (44(1)):165-171 doi:10.1007/s40618-020-01286-6.

Should Total Thyroidectomy Be Recommended for Patients with Familial Non-medullary Thyroid Cancer?

Kim YS, Seo M, Park SH, et al.

World journal of surgery 2020; (44(9)):3022-3027 doi:10.1007/s00268-020-05473-7.

Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy.

Hawkins Carranza F, Guadalix Iglesias S, Luisa De Mingo Domínguez M, et al.

Cancer medicine 2020; (9(16)):5746-5755 doi:10.1002/cam4.3200.

The Impact of the Extent of Surgery on the Long-Term Outcomes of Patients with Low-Risk Differentiated Non-Medullary Thyroid Cancer: A Systematic Meta-Analysis.

Bojoga A, Koot A, Bonenkamp J, et al.

Journal of clinical medicine 2020; (9(7)) doi:10.3390/jcm9072316.

Personalized management of differentiated thyroid cancer in real life - practical guidance from a multidisciplinary panel of experts.

Campennì A, Barbaro D, Guzzo M, et al.

Endocrine 2020; (70(2)):280-291 doi:10.1007/s12020-020-02418-x.

Comparison Between Familial and Sporadic Non-medullary Thyroid Carcinoma: A Retrospective Individual Risk Factor-Matched Cohort Study.

Lee YM, Jeon MJ, Kim WW, et al.

Annals of surgical oncology 2021; (28(3)):1722-1730 doi:10.1245/s10434-020-09025-0.

Familial non-medullary thyroid cancer: a critical review.

Capezzone M, Robenshtok E, Cantara S, Castagna MG

Journal of endocrinological investigation 2021; (44(5)):943-950 doi:10.1007/s40618-020-01435-x.

Familial non-medullary thyroid carcinoma: clinico-pathological features, current knowledge and novelty regarding genetic risk factors.

Cirello V

Minerva endocrinology 2021; (46(1)):5-20 doi:10.23736/S2724-6507.20.03338-6.

A review on age-related cancer risks in PTEN hamartoma tumor syndrome.

Hendricks LAJ, Hoogerbrugge N, Schuurs-Hoeijmakers JHM, Vos JR

Clinical genetics 2021; (99(2)):219-225 doi:10.1111/cge.13875.

Role of Age at Diagnosis in Defining Potential Familial Nonmedullary Thyroid Cancer in Kindreds With Two Affected Members.

Capezzone M, Sagnella A, Pilli T, et al.

The Journal of clinical endocrinology and metabolism 2021; (106(2)):e855-e865 doi:10.1210/clinem/dgaa798.

Familial non medullary thyroid carcinoma: Beyond the syndromic forms.

Orois A, Mora M, Halperin I, Oriola J

Endocrinologia, diabetes y nutricion 2021; (68(4)):260-269 doi:10.1016/j.endinu.2020.08.002.

Distress, anxiety, depression and unmet needs in thyroid cancer survivors: a longitudinal study.

Dionisi-Vici M, Fantoni M, Botto R, et al.

Endocrine 2021; (74(3)):603-610 doi:10.1007/s12020-021-02786-y.

Clinical characteristics and prognosis of familial nonmedullary thyroid carcinoma.

de Carlos Artajo J, Irigaray Echarri A, García Torres J, et al.

Endocrinologia, diabetes y nutricion 2021; doi:10.1016/j.endinu.2021.04.012.

Dermatological and endocrine elements in Carney complex (Review).

Sandru F, Dumitrascu MC, Petca A, et al.

Experimental and therapeutic medicine 2021; (22(5)):1313 doi:10.3892/etm.2021.10748.

Papillary Thyroid Cancer Affecting Multiple Family Members: A Case Report and Literature Review of Familial Nonmedullary Thyroid Cancer.

Baagar KA, Alowainati BI

Case reports in endocrinology 2021; (2021()):3472000 doi:10.1155/2021/3472000.

A New Dynamic Response to Therapy Assessment in Postoperative Patients With Low-Risk Differentiated Thyroid Cancer Treated Without Radioactive Iodine.

Dong P, Wang L, Xiao L, et al.

Frontiers in oncology 2021; (11()):764258 doi:10.3389/fonc.2021.764258.

Susceptibility Genes and Chromosomal Regions Associated With Non-Syndromic Familial Non-Medullary Thyroid Carcinoma: Some Pathogenetic and Diagnostic Keys.

Sánchez-Ares M, Cameselle-García S, Abdulkader-Nallib I, et al.

Frontiers in endocrinology 2022; (13()):829103 doi:10.3389/fendo.2022.829103.

Radioactive Iodine for Papillary Thyroid Carcinoma.

Chan WWL, Kwong DLW

Methods in molecular biology (Clifton, N.J.) 2022; (2534()):225-241 doi:10.1007/978-1-0716-2505-7_16.

Strategies for Radioiodine Treatment: What's New.

Sparano C, Moog S, Hadoux J, et al.

Cancers 2022; (14(15)) doi:10.3390/cancers14153800.

Prevalence of Thyroid Nodules and Thyroid Cancer in Individuals with a First-Degree Family History of Non-Medullary Thyroid Cancer: A Cross-Sectional Study Based on Sonographic Screening.

Grani G, Lamartina L, Montesano T, et al.

Thyroid : official journal of the American Thyroid Association 2022; (32(11)):1392-1401 doi:10.1089/thy.2022.0253.

Ultrasonography screening in children and adolescents who have one parent with familial non-medullary thyroid carcinoma.

Rosario PW, Mourão GF

Journal of paediatrics and child health 2022; (58(12)):2254-2257 doi:10.1111/jpc.16215.

Application and prospect of trabecular bone score in differentiated thyroid cancer patients receiving thyrotropin suppression therapy.

Ran B, Wei F, Gong J, Xu H

Frontiers in endocrinology 2022; (13()):1004962 doi:10.3389/fendo.2022.1004962.

Lobo-isthmectomy in the management of differentiated thyroid cancer.

Krajewska J, Kukulska A, Samborski K, et al.

Thyroid research 2023; (16(1)):4 doi:10.1186/s13044-022-00145-1.

Thyroglobulin Value Predict Iodine-123 Imaging Result in Differentiated Thyroid Cancer Patients.

Campennì A, Ruggeri RM, Siracusa M, et al.

Cancers 2023; (15(8)) doi:10.3390/cancers15082242.

Prophylactic Central Neck Dissection Based on Preoperative Imaging and Intraoperative Surgeon's Palpation Versus Total Thyroidectomy Alone for Papillary Thyroid Cancer.

Yuan Q, Yang Y, Li C, et al.

The Journal of surgical research 2023; (290()):126-132 doi:10.1016/j.jss.2023.03.035.

Cardiovascular Outcomes of Differentiated Thyroid Cancer Patients on Long Term TSH Suppression: A Systematic Review and Meta-Analysis.

Yu J, Kaur R, Ayeni FE, et al.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2023; (55(6)):379-387 doi:10.1055/a-2084-3408.

Role of prophylactic central neck lymph node dissection for papillary thyroid carcinoma in the era of de-escalation.

Pavlidis ET, Pavlidis TE

World journal of clinical oncology 2023; (14(7)):247-258 doi:10.5306/wjco.v14.i7.247.

Familial nonmedullary thyroid cancer: a case series in Iranian patients with a meta-review of case series.

Mohammadi Zaniani Z, Zeinalian M, Tabatabaiefar MA

Laboratory medicine 2024; (55(4)):506-516 doi:10.1093/labmed/lmad098.

Fear of Cancer Recurrence in Differentiated Thyroid Cancer Survivors: A Systematic Review.

Hampton J, Alam A, Zdenkowski N, et al.

Thyroid : official journal of the American Thyroid Association 2024; (34(5)):541-558 doi:10.1089/thy.2023.0642.

Chromosomal localization of mutated genes in non-syndromic familial thyroid cancer.

Jiang YJ, Xia Y, Han ZJ, et al.

Frontiers in oncology 2024; (14()):1286426 doi:10.3389/fonc.2024.1286426.

The Effect of Thyrotropin Suppression on Survival Outcomes in Patients with Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis.

Gubbi S, Al-Jundi M, Foerster P, et al.

Thyroid : official journal of the American Thyroid Association 2024; (34(6)):674-686 doi:10.1089/thy.2023.0711.

Surveillance-Associated Anxiety After Curative-Intent Cancer Surgery: A Systematic Review.

Khatri R, Quinn PL, Wells-Di Gregorio S, et al.

Annals of surgical oncology 2025; (32(1)):47-62 doi:10.1245/s10434-024-16287-5.

[Thyroid cancer in a child with Cowden syndrome].

Bricheva EB, Nagaeva EV, Brovin DN, et al.

Problemy endokrinologii 2024; (70(5)):84-90 doi:10.14341/probl13445.

Update on Pediatric Surveillance Recommendations for PTEN Hamartoma Tumor Syndrome, DICER1-Related Tumor Predisposition, and Tuberous Sclerosis Complex.

Schultz KAP, MacFarland SP, Perrino MR, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2025; (31(2)):234-244 doi:10.1158/1078-0432.CCR-24-1947.

Association Between Serum Thyrotropin and Cancer Recurrence in Differentiated Thyroid Cancer: A Population-Based Retrospective Cohort Study.

Qiang JK, Sutradhar R, Everett K, et al.

Thyroid : official journal of the American Thyroid Association 2025; (35(2)):208-215 doi:10.1089/thy.2024.0330.

Approach to the Patient With Thyroid Cancer: Selection and Management of Candidates for Lobectomy.

Robenshtok E, Bachar G, Ritter A

The Journal of clinical endocrinology and metabolism 2025; (110(7)):e2327-e2337 doi:10.1210/clinem/dgae903.

Cancer and Overgrowth Manifestations of PTEN Hamartoma Tumor Syndrome: Management Recommendations from the International PHTS Consensus Guidelines Working Group.

Dhawan A, Baitamouni S, Liu D, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2025; (31(9)):1754-1765 doi:10.1158/1078-0432.CCR-24-3819.

Examining the Sequential Relationships Between Voice Changes, Symptom Experiences, Fear of Cancer Recurrence, and Voice-Related Quality of Life in Patients With Thyroid Cancer: A Cross-sectional Study.

Lee MK, Oh J

Cancer nursing 2026; (49(5)):373-380 doi:10.1097/NCC.0000000000001466.

The efficacy analysis of radioactive iodine therapy for familial non-medullary thyroid cancer in the era of personalized medicine: a cohort study and a meta-analysis.

Cao J, Li X, Liang H, et al.

Annals of nuclear medicine 2025; (39(6)):535-545 doi:10.1007/s12149-025-02029-4.

Comparison of Progression-Free Survival in Familial Non-Medullary Thyroid Cancer and Sporadic Differentiated Thyroid Cancer Patients.

Chuki E, Behairy N, Auh S, et al.

Thyroid : official journal of the American Thyroid Association 2025; (35(6)):642-651 doi:10.1089/thy.2024.0588.

Thyroid Cancer Survivors Experience Persistent Symptoms and Health-Related Quality-of-Life Deficits 12 Months Following Surgery.

O'Neill CJ, Rowe CW, Morris-Baguley H, et al.

Thyroid : official journal of the American Thyroid Association 2025; (35(9)):1039-1051 doi:10.1089/thy.2025.0149.

Relationship between affected family members and clinical aggressiveness in Familial non-medullary thyroid carcinoma: a systematic review and meta-analysis.

Yang G, Tian Y, Zhang Y, et al.

Endocrine 2025; (90(3)):1149-1167 doi:10.1007/s12020-025-04413-6.

Familial Non-Medullary Thyroid Carcinoma: Distinct Clinicopathological Features and Prognostic Implications in a Large Cohort of 46,572 Patients.

Lee CR, Kim JK, Ho J, et al.

Cancers 2025; (17(20)) doi:10.3390/cancers17203381.

Dermatologic Features of Endocrine Tumor Syndromes-Systematic Review and Meta-Analysis.

Pálla S, Metyovinyi Z, Meznerics FA, et al.

International journal of dermatology 2026; (65(3)):464-488 doi:10.1111/ijd.70118.

The genetic puzzle of FAP: exploring novel diagnostic approaches for APC/MUTYH-negative case.

Grot N, Kazimierczyk M, Szuman M, et al.

Hereditary cancer in clinical practice 2025; (23(1)):25 doi:10.1186/s13053-025-00318-7.

Recurrence factors in familial papillary thyroid carcinoma.

Ríos A, Amunategui I, Ruiz Pardo J, et al.

Minerva endocrinology 2026; (51(1)):4-16 doi:10.23736/S2724-6507.25.04264-2.

Unmasking familial follicular cell-derived thyroid neoplasms associated with syndromes: DICER1 and PTEN-hamartoma tumor syndromes.

Riascos MC, Agaimy A, Nosé V

Virchows Archiv : an international journal of pathology 2026; (488(1)):147-157 doi:10.1007/s00428-025-04384-z.

Differences in the aggressiveness of familial versus sporadic non-medullary thyroid cancer: An unresolved controversy.

Miasaki FY, Cavalcanti TCS, Graf H, et al.

Archives of endocrinology and metabolism 2026; (70(2)) doi:10.20945/2359-4292-2026-0018.

Familial papillary thyroid cancer; A male case with breast and thyroid cancer and his three sisters with thyroid cancer: A case series and review of the literature.

Fırat SN, Durhan A

Indian journal of cancer 2025; (62(4)):552-556 doi:10.4103/ijc.ijc_520_22.

Validation of the Czech version of the nine-item Fear of Cancer Recurrence Inventory in differentiated thyroid cancer survivors.

Nemcikova P, Javurkova A, Raudenska J, et al.

Endocrine 2026; (91(1)).

Familial Status Modulates the Stability of Excellent Response in Non-Medullary Thyroid Carcinoma: Implications for Tailored Surveillance.

Valerio L, Sagnella A, Maino F, et al.

Cancers 2026; (18(10)) doi:10.3390/cancers18101525.

Recognizing Familial Thyroid Neoplasia: The Pathologist's Role in Diagnosis and Management.

Nosé V, Canberk S, Baloch Z

Advances in anatomic pathology 2026; (33(4)):291-303 doi:10.1097/PAP.0000000000000543.

ERN GENTURIS cancer surveillance guideline for individuals with PTEN hamartoma tumour syndrome (PHTS).

Hoogerbrugge N, Blatnik A, Lautrup CK, et al.

European journal of human genetics : EJHG 2026; doi:10.1038/s41431-026-02181-z.

Genetic endocrine tumors focusing on the thyroid.

Ginzberg SP, Weller JHD, Skefos CM, Perrier ND

Best practice & research. Clinical endocrinology & metabolism 2026; 102158 doi:10.1016/j.beem.2026.102158.

Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers, Part II: Follow-up Surveillance after Initial Treatment 2026.

Lee EK, Kang SH, Koo BS, et al.

Endocrinology and metabolism (Seoul, Korea) 2026; (41(4)):493-534 doi:10.3803/EnM.2026.3149.